Profile: Acorda Therapeutics Inc (ACOR.O)
7 Mar 2014
Acorda Therapeutics, Inc. (Acorda), incorporated on March 17, 1995, is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.
Ampyra is an oral drug used as a treatment to improve walking in patients with MS. Ampyra can be used alone or with concurrent medications, including immunomodulatory drugs. The majority of patients in the Company's two Phase 3 clinical trials for Ampyra (63%) were taking immunomodulatory drugs (interferons, glatiramer acetate, or natalizumab). Ampyra is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously referred to as fampridine.
Zanaflex Capsules and Zanaflex tablets contain tizanidine hydrochloride, one of the two active ingredients used for the management of spasticity. The Company is developing the lead antibody (rHIgM22) as a therapeutic for MS. On February 6, 2012, the Company launched an authorized generic version of tizanidine hydrochloride capsules under its agreement with Watson Pharma, Inc., a subsidiary of Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.), following the launch by Apotex of its generic tizanidine hydrochloride capsules.
Neuregulins form a family of growth factors-related to epidermal growth factor. These molecules bind to erbB receptors, which translate the growth factor signal to the cell and cause changes in cell growth, protein production and gene expression. Neuregulins covered in the portfolio from CeNeS have a number of applications. Neuregulins offers the Company for multiple CNS and cardiac indications, including MS, stroke and heart failure as well as protection from chemotherapy-induced damage.
Antibodies/Remyelinating Antibodies Program
The Company’s remyelinating antibodies program is based on its research collaboration with Mayo Foundation for Medical Education and Research (Mayo Clinic). It has worldwide rights to patents and other intellectual property for these antibodies related to nervous system disorders.
The Company has developed a program based on the concept of breaking down the matrix of scar tissue that develops as a result of an injury to the CNS. Component of these two forms of matrix are chondroitin sulfate proteoglycans (CSPGs). Acorda has tested the ability of Chondroitinase ABC-I to improve function in an animal model of spinal cord injury.
The Company competes with Biogen Idec, Schering AG, Teva Pharmaceutical Industries, Ltd., Merck Serono, Biogen-IDEC, Elan, Novartis AG, BioMarin Pharmaceutical Inc. (BioMarin) and EUSA Pharma.95
Acorda Therapeutics Inc
420 Saw Mill River Road
ARDSLEY NY 10502